At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,449 enrolled
Drug / intervention
Olmesartan medoxomil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)
In Brief
A Phase 3 clinical trial evaluating Olmesartan medoxomil and Placebo Tablets for Diabetes Mellitus, Type 2 and 2 related conditions. Completed, enrolled 4,449 participants across 1 site.
Detailed Summary
This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
First PostedSep 2005
Primary CompletionJul 2009
TodayJul 2026
First PostedSep 16, 2005
Enrollment StartOct 1, 2004
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.8 years ago
Interventions
Olmesartan medoxomildrug
tablets
Placebo Tabletsdrug
Tablets